title: Biosimilars: company strategies to capture value from the biologics market.
abstract: Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to enter the biosimilars market: research and development, manufacturing, supporting activities, marketing, and lobbying. Understanding the importance of each of these capabilities will be key to maximising the value generated from the biologics patent cliff.
authors.affiliation: Escuela Técnica Superior de Ingeniería, Universidad de Santiago de Compostela, Rúa Lope Gómez de Marzoa s/n, Campus Vida 15782, Santiago de Compostela, Spain. bruno.calo@rai.usc.es.
authors.forename: Bruno
authors.initials: B
authors.lastname: Calo-Fernández
authors.forename: Juan Leonardo
authors.initials: JL
authors.lastname: Martínez-Hurtado